Panhematin
Payments companies reported to CMS as associated with Panhematin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Panhematin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Panhematin
These are the largest totals companies reported as associated with Panhematin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amy Dickey | Seattle, WA | Pulmonary Disease | $28,735.41 |
| Roy Smith | Erie, PA | Medical Oncology | $27,084.19 |
| Bruce Wang | San Francisco, CA | Gastroenterology (Internal Medicine) | $22,635.78 |
| Akshata Moghe | League City, TX | Gastroenterology (Internal Medicine) | $21,242.38 |
| Manish Thapar | Philadelphia, PA | Transplant Hepatology | $16,764.32 |
| Rebecca Karp | Boston, MA | Hematology & Oncology | $16,237.71 |
| Pierre Gholam | Cleveland, OH | Gastroenterology (Internal Medicine) | $15,519.34 |
| Manisha Balwani | New York, NY | Clinical Genetics (M.D.) | $14,967.12 |
| Samuel Silver | Ann Arbor, MI | Hematology (Internal Medicine) | $4,875.00 |
| Neil Nagovski | Miami, FL | Hematology & Oncology | $4,400.00 |
Prescribed Panhematin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.